Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Klinikum Der Technischen Universität München (Tum Klinkum) manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is handled by examiner BATES, KEENAN ALEXANDER. The portfolio involves 1 distinct examiner and 1 distinct art unit. BATES, KEENAN ALEXANDER is the busiest examiner with 1 pending action.
This single matter represents the total pending prosecution activity for the portfolio. The involvement of 1 distinct examiner and 1 distinct art unit suggests that the current prosecution is highly focused. This centralized structure means that the applicant's primary interaction is with a single examiner within the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BATES, KEENAN ALEXANDER | 1 | 45.5% | +79.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18034226 | AN IMMUNE CHECKPOINT-MODULATING VSV-NDV HYBRID VIRUS FOR ONCOLYTIC VIRUS IMMUNOTHERAPY OF CANCER | BATES, KEENAN ALEXANDER | 5d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18034226 | AN IMMUNE CHECKPOINT-MODULATING VSV-NDV HYBRID VIRUS FOR ONCOLYTIC VIRUS IMMUNOTHERAPY OF CANCER | BATES, KEENAN ALEXANDER | 5d |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18034226 | AN IMMUNE CHECKPOINT-MODULATING VSV-NDV HYBRID VIRUS FOR ONCOLYTIC VIRUS IMMUNOTHERAPY OF CANCER | BATES, KEENAN ALEXANDER | 1631 | §103§112Other | Final Rejection | 5d | Pending | Apr 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial